Free Trial
→ Top Trader Reveals Stunning Black Friday Deal (From Base Camp Trading) (Ad)tc pixel Free PPCB Stock Alerts

Propanc Biopharma (PPCB) Financials

Propanc Biopharma logo
$1.86 +0.02 (+0.82%)
Closing price 11/12/2026 03:54 PM Eastern
Extended Trading
$1.94 +0.08 (+4.31%)
As of 11/12/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Propanc Biopharma

Annual Income Statements for Propanc Biopharma

This table shows Propanc Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.41 -7.87 -7.04 -5.76 -9.48 -2.42 -3.36 -3.13 -2.01 -59 -20
Consolidated Net Income / (Loss)		 -9.41 -7.87 -7.04 -5.76 -4.74 -2.03 -2.66 -2.66 -1.82 -59 -19
Net Income / (Loss) Continuing Operations		 -9.41 -7.87 -7.04 -5.76 -4.74 -2.03 -2.66 -2.66 -1.82 -59 -19
Total Pre-Tax Income 		-9.48 -8.17 -7.22 -5.87 -4.88 -2.14 -2.71 -2.79 -1.95 -59 -19
Total Operating Income		 -6.90 -5.74 -3.96 -2.61 -3.49 -1.81 -1.99 -1.78 -1.54 -57 -18
Total Gross Profit		 -0.02 -0.03 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 0.02 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 6.87 5.71 3.93 2.61 3.49 1.81 1.99 1.78 1.54 57 18
Selling, General & Admin Expense		 5.43 4.74 2.10 2.33 3.28 1.55 1.71 1.50 1.25 34 15
Research & Development Expense		 1.45 0.97 1.83 0.26 0.18 0.23 0.26 0.25 0.25 0.22 0.63
Other Operating Expenses / (Income)		 - - - 0.03 0.03 0.03 0.03 0.03 0.03 23 2.32
Total Other Income / (Expense), net		 -2.59 -2.43 -3.26 -3.26 -1.38 -0.33 -0.72 -1.01 -0.41 -1.65 -0.68
Interest Expense		 5.16 3.20 2.54 0.11 1.68 0.40 0.59 0.51 0.61 1.43 0.30
Interest & Investment Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00
Other Income / (Expense), net		 2.57 0.77 -0.72 -3.15 0.30 0.07 -0.14 -0.51 0.20 -0.21 -0.38
Income Tax Expense		 -0.07 -0.31 -0.18 -0.12 -0.13 -0.11 -0.05 -0.13 -0.13 0.00 0.00
Preferred Stock Dividends Declared		 - - - - 0.00 0.39 0.70 0.47 0.19 0.00 0.93
Basic Earnings per Share		 ($4.83) ($2.24) ($178.75) ($10.97) ($192.45) ($0.80) ($49.23) ($1.80) ($1,420.53) ($371.22) ($17.62)
Weighted Average Basic Shares Outstanding		 1.95M 3.51M 39.38K 524.94K 24.63K 3.03M 68.22K 1.74M 1.42K 158.73K 1.12M
Diluted Earnings per Share		 ($4.83) ($2.24) ($178.75) ($10.97) ($192.45) - ($49.23) ($1.80) ($1,420.53) ($371.22) ($17.62)
Weighted Average Diluted Shares Outstanding		 1.95M 3.51M 39.38K 524.94K 24.63K 3.03M 68.22K 1.74M 1.42K 158.73K 1.12M
Weighted Average Basic & Diluted Shares Outstanding		 1.95M 3.51M 39.38K 524.94K 24.63K 3.03M 677.18M 14.83M 688.02M 12.81M 6.33M

Quarterly Income Statements for Propanc Biopharma

This table shows Propanc Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.62 -0.54 -0.36 -0.35 -0.43 -54 -4.07 -4.84 -4.02 -6.36 -4.57
Consolidated Net Income / (Loss)		 -0.58 -0.53 -0.36 -0.35 -0.43 -54 -4.07 -4.84 -3.09 -6.36 -4.57
Net Income / (Loss) Continuing Operations		 -0.58 -0.53 -0.36 -0.35 -0.43 -54 -4.07 -4.84 -3.09 -6.36 -4.57
Total Pre-Tax Income 		-0.71 -0.53 -0.36 -0.35 -0.43 -54 -4.07 -4.84 -3.09 -6.36 -4.57
Total Operating Income		 -0.44 -0.42 -0.26 -0.29 -0.21 -53 -3.65 -4.67 -3.65 -6.40 -3.46
Total Operating Expenses		 0.44 0.42 0.26 0.29 0.21 53 3.65 4.67 3.65 6.40 3.46
Selling, General & Admin Expense		 0.32 0.35 0.19 0.22 0.15 53 -20 4.60 3.63 6.22 0.80
Research & Development Expense		 0.11 0.07 0.05 0.06 0.05 0.05 0.05 0.06 0.02 0.17 0.38
Other Operating Expenses / (Income)		 0.01 0.01 0.01 0.01 0.01 0.01 23 0.01 0.01 0.01 2.28
Total Other Income / (Expense), net		 -0.27 -0.11 -0.10 -0.06 -0.22 -0.94 -0.43 -0.16 0.56 0.04 -1.12
Interest Expense		 0.26 0.14 0.06 0.10 0.14 0.91 0.29 0.11 0.04 0.11 0.03
Interest & Investment Income		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income / (Expense), net		 -0.01 0.03 -0.04 0.03 -0.08 0.03 -0.20 -0.05 0.61 0.15 -1.09
Basic Earnings per Share		 ($1,559.55) ($545.79) $684.85 ($35.97) ($32.23) ($12.50) ($25.65) ($0.39) ($0.30) ($0.28) ($4.07)
Weighted Average Basic Shares Outstanding		 397.00 994.00 1.42K 9.85K 13.35K 4.33M 158.73K 12.33M 13.36M 22.43M 1.12M
Diluted Earnings per Share		 ($1,559.55) ($545.79) $684.85 ($35.97) ($32.23) ($12.50) ($25.65) ($0.39) ($0.30) ($0.28) ($4.07)
Weighted Average Diluted Shares Outstanding		 397.00 994.00 1.42K 9.85K 13.35K 4.33M 158.73K 12.33M 13.36M 22.43M 1.12M
Basic & Diluted Earnings per Share		 - - - - - - ($25.65) - - - ($4.07)
Weighted Average Basic & Diluted Shares Outstanding		 52.14M 167.98M 688.02M 789.90M 15.37K 11.61M 12.81M 13.36M 15.86M 56.96M 6.33M

Annual Cash Flow Statements for Propanc Biopharma

This table details how cash moves in and out of Propanc Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 0.01 -0.05 -0.05 0.15 0.06 -0.06 0.00 0.01 0.01 -0.01 0.82
Net Cash From Operating Activities		 -4.50 -2.05 -2.18 -2.06 -1.85 -1.15 -1.44 -1.11 -0.94 -0.41 -5.68
Net Cash From Continuing Operating Activities		 -4.50 -2.05 -1.67 -1.97 -1.85 -1.15 -1.44 -1.11 -0.94 -0.41 -5.68
Net Income / (Loss) Continuing Operations		 -9.41 -7.87 -7.04 -5.76 -4.74 -2.03 -2.66 -2.66 -1.82 -59 -19
Consolidated Net Income / (Loss)		 -9.41 -7.87 -7.04 -5.76 -4.74 -2.03 -2.66 -2.66 -1.82 -59 -19
Depreciation Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization Expense		 4.19 3.08 2.64 0.39 1.57 0.34 0.50 0.46 0.60 0.32 0.27
Non-Cash Adjustments To Reconcile Net Income		 0.48 2.11 1.34 3.27 1.11 0.10 0.55 0.62 -0.13 57 13
Changes in Operating Assets and Liabilities, net		 0.24 0.62 0.88 0.12 0.21 0.44 0.17 0.47 0.42 1.14 -0.58
Net Cash From Investing Activities		 -0.01 0.00 0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.00
Net Cash From Continuing Investing Activities		 -0.01 0.00 0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.00
Purchase of Property, Plant & Equipment		 -0.01 - 0.00 -0.00 - - - - - 0.00 -0.00
Net Cash From Financing Activities		 4.54 2.10 2.40 2.12 1.89 1.06 1.49 1.11 0.94 0.49 6.46
Net Cash From Continuing Financing Activities		 4.54 2.10 2.40 2.12 1.89 1.06 1.49 1.11 0.94 0.49 6.46
Repayment of Debt		 -0.45 -0.02 -0.49 -0.34 0.00 -0.04 - 0.00 -0.14 -0.40 -1.06
Issuance of Debt		 4.98 1.65 2.89 1.37 1.47 0.33 0.77 0.59 1.06 0.89 0.25
Issuance of Preferred Equity		 - - - - - - - - - 0.00 0.95
Issuance of Common Equity		 0.00 - 0.00 1.10 0.45 0.00 0.10 0.02 0.02 0.00 3.31
Other Financing Activities, net		 - 0.46 0.00 0.00 0.00 0.78 0.63 0.50 - 0.00 3.00
Effect of Exchange Rate Changes		 -0.01 -0.10 - - 0.02 0.02 - -0.00 0.00 -0.09 0.05
Cash Interest Paid		 0.01 0.00 0.02 0.10 0.01 0.01 0.00 0.00 0.01 0.03 0.13
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Propanc Biopharma

This table details how cash moves in and out of Propanc Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 0.07 -0.07 0.01 -0.01 0.01 0.04 -0.04 0.59 -0.04 -0.12 0.39
Net Cash From Operating Activities		 -0.24 -0.10 -0.26 -0.24 0.02 -0.10 -0.09 -1.94 -1.00 -1.14 -1.60
Net Cash From Continuing Operating Activities		 -0.24 -0.10 -0.26 -0.24 0.02 -0.10 -0.09 -1.94 -1.00 -1.14 -1.60
Net Income / (Loss) Continuing Operations		 -0.58 -0.53 -0.36 -0.35 -0.43 -54 -4.07 -4.84 -3.09 -6.36 -4.57
Consolidated Net Income / (Loss)		 -0.58 -0.53 -0.36 -0.35 -0.43 -54 -4.07 -4.84 -3.09 -6.36 -4.57
Depreciation Expense		 0.00 0.00 - 0.00 - - - 0.00 0.00 0.00 0.00
Amortization Expense		 0.25 0.11 0.07 0.06 0.08 0.06 0.12 0.19 0.04 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.01 -0.03 0.13 -0.01 0.11 54 3.29 3.62 1.80 5.23 2.85
Changes in Operating Assets and Liabilities, net		 0.09 0.34 -0.10 0.07 0.26 0.23 0.58 -0.91 0.25 -0.03 0.10
Net Cash From Investing Activities		 - - - 0.00 - - - -0.00 -0.00 -0.00 -0.00
Net Cash From Continuing Investing Activities		 - - - 0.00 - - - -0.00 -0.00 -0.00 -0.00
Purchase of Property, Plant & Equipment		 - - - 0.00 - - - -0.00 -0.00 -0.00 -0.00
Net Cash From Financing Activities		 0.27 0.07 0.25 0.22 0.05 0.15 0.07 2.53 0.97 0.98 1.98
Net Cash From Continuing Financing Activities		 0.27 0.07 0.25 0.22 0.05 0.15 0.07 2.53 0.97 0.98 1.98
Repayment of Debt		 - - - 0.00 -0.12 -0.05 -0.22 -1.04 0.02 -0.02 -0.02
Other Financing Activities, net		 - - - - - - - - - - 2.00
Effect of Exchange Rate Changes		 0.03 -0.03 0.02 0.01 -0.07 -0.02 -0.02 - - 0.04 0.01
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.12 -0.00 0.01 0.00

Annual Balance Sheets for Propanc Biopharma

This table presents Propanc Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Total Assets		 0.38 0.10 0.07 0.10 0.10 0.01 0.08 0.06 0.07 20 13
Total Current Assets		 0.36 0.08 0.06 0.09 0.07 0.01 0.02 0.02 0.03 8.35 8.54
Cash & Equivalents		 0.12 0.07 0.02 0.00 0.07 0.00 0.00 0.01 0.02 0.01 0.83
Prepaid Expenses		 0.21 0.00 0.03 0.08 - 0.00 0.01 0.01 0.00 8.33 7.66
Current Deferred & Refundable Income Taxes		 0.03 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.01
Other Current Assets		 - - - - - - - - 0.00 0.00 0.03
Plant, Property, & Equipment, net		 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.02 0.00 0.06 0.04 0.05 11 4.23
Other Noncurrent Operating Assets		 0.00 - - 0.00 0.02 0.00 0.06 0.04 0.05 11 4.23
Total Liabilities & Shareholders' Equity		 0.38 0.10 0.07 0.10 0.10 0.01 0.08 0.06 0.07 20 13
Total Liabilities		 2.94 5.54 6.82 4.40 3.74 3.08 3.11 3.18 3.85 5.73 3.38
Total Current Liabilities		 2.94 5.54 6.82 4.40 3.74 3.08 3.06 3.16 3.79 5.58 3.35
Short-Term Debt		 1.20 3.48 4.70 1.66 1.56 0.62 0.98 0.51 0.87 1.56 0.46
Accounts Payable		 0.54 1.00 1.55 1.67 1.58 1.93 1.41 1.55 2.01 2.74 1.99
Current Employee Benefit Liabilities		 1.09 1.00 0.51 0.32 0.53 0.42 0.42 0.59 0.64 0.67 0.75
Other Current Liabilities		 0.11 0.06 0.05 0.75 0.08 0.11 0.20 0.47 0.18 0.42 0.02
Other Current Nonoperating Liabilities		 - - - - - - 0.06 0.04 0.09 0.19 0.13
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.02 0.06 0.15 0.02
Long-Term Debt		 - - - - - - - 0.00 0.06 0.11 0.00
Other Noncurrent Operating Liabilities		 - - - - - 0.00 0.04 0.02 0.00 0.04 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -2.57 -5.44 -6.75 -4.30 -3.64 -3.07 -3.02 -3.12 -3.78 14 9.40
Total Preferred & Common Equity		 -2.57 -5.44 -6.75 -4.30 -3.64 -3.07 -3.02 -3.12 -3.78 14 9.40
Preferred Stock		 - - 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00
Total Common Equity		 -2.57 -5.45 -6.76 -4.31 -3.65 -3.07 -3.03 -3.12 -3.78 14 9.40
Common Stock		 28 33 38 46 51 54 57 60 62 138 153
Retained Earnings		 -30 -38 -45 -51 -56 -58 -62 -65 -67 -126 -144
Treasury Stock		 0.00 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05
Accumulated Other Comprehensive Income / (Loss)		 0.13 -0.14 0.36 1.07 1.27 1.09 1.23 1.29 1.27 1.32 1.18
Other Equity Adjustments		 - - - - 0.00 0.00 -0.02 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for Propanc Biopharma

This table presents Propanc Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 0.24 0.04 0.06 0.08 23 18 15 14
Total Current Assets		 0.21 0.01 0.02 0.02 9.74 8.76 7.71 8.22
Cash & Equivalents		 0.07 0.01 0.01 0.01 0.05 0.60 0.56 0.44
Prepaid Expenses		 0.01 0.00 0.01 0.00 9.68 8.14 7.13 7.73
Current Deferred & Refundable Income Taxes		 0.00 0.01 0.00 0.00 - 0.01 0.02 0.01
Other Current Assets		 0.12 - - - 0.00 0.01 0.00 0.04
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.03 0.02 0.04 0.06 13 9.21 7.40 6.11
Other Noncurrent Operating Assets		 0.03 0.02 0.04 0.06 13 9.21 7.40 6.11
Total Liabilities & Shareholders' Equity		 0.24 0.04 0.06 0.08 23 18 15 14
Total Liabilities		 3.81 3.74 4.17 4.24 4.44 3.61 3.66 3.51
Total Current Liabilities		 3.76 3.69 4.10 4.15 4.34 3.57 3.62 3.48
Short-Term Debt		 0.95 0.86 1.02 1.12 1.15 0.63 0.59 0.52
Accounts Payable		 1.85 1.95 2.11 2.12 2.20 1.91 1.82 1.92
Current Employee Benefit Liabilities		 0.62 0.61 0.68 0.61 0.62 0.69 0.70 0.74
Other Current Liabilities		 0.27 0.18 0.18 0.17 0.19 0.19 0.34 0.18
Other Current Nonoperating Liabilities		 0.07 0.08 0.11 0.14 0.17 0.15 0.17 0.12
Total Noncurrent Liabilities		 0.04 0.05 0.07 0.08 0.09 0.04 0.04 0.03
Long-Term Debt		 0.04 0.05 0.07 0.08 0.09 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.01 0.00 - - - 0.04 0.04 0.03
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - 1.00 1.00
Total Equity & Noncontrolling Interests		 -3.56 -3.70 -4.11 -4.16 18 14 10 9.83
Total Preferred & Common Equity		 -3.56 -3.70 -4.11 -4.16 18 14 10 9.83
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -3.56 -3.70 -4.11 -4.16 18 14 10 9.83
Common Stock		 61 61 62 62 138 144 144 149
Retained Earnings		 -66 -66 -67 -67 -122 -130 -134 -141
Treasury Stock		 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05
Accumulated Other Comprehensive Income / (Loss)		 1.23 1.34 1.17 1.49 1.46 1.34 1.33 1.23
Other Equity Adjustments		 -0.01 0.00 - - - 0.00 0.00 0.03

Annual Metrics And Ratios for Propanc Biopharma

This table displays calculated financial ratios and metrics derived from Propanc Biopharma's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
DEI Shares Outstanding		 721,929,520.00 3,751,876.00 38,324,191.00 420,800,048.00 47,086,442.00 5,967,110.00 122,193,541.00 3,288,404,722.00 167,978,843.00 11,611,782.00 56,959,280.00
DEI Adjusted Shares Outstanding		 721,929,520.00 3,751,876.00 38,324,191.00 420,800,048.00 47,086,442.00 5,967,110.00 122,193,541.00 3,288,404,722.00 167,978,843.00 464,471.00 2,278,371.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.01 -2.10 -0.18 -0.01 -0.20 -0.41 -0.03 0.00 -0.01 -126.86 -8.69
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 88.82% -1,307.33% -7.97% -163.20% 69.81% 13.58% -16.04% -12.21% 59.28% -7,593.03% 68.00%
EBIT Growth		 -70.28% -14.85% 5.84% -23.13% 44.56% 45.53% -22.51% -7.09% 41.39% -4,195.18% 67.71%
NOPAT Growth		 -304.41% 16.78% 31.01% 33.97% -33.64% 48.14% -9.86% 10.76% 13.54% -3,628.93% 68.25%
Net Income Growth		 -175.74% 16.40% 10.53% 18.20% 17.67% 57.27% -31.20% -0.09% 31.57% -3,136.61% 67.99%
EPS Growth		 -24,050.00% 53.62% -7,879.91% 93.86% -1,654.33% 0.00% 0.00% 96.34% -78,818.33% -3,136.61% 95.25%
Operating Cash Flow Growth		 -215.57% 54.45% -6.19% 5.40% 10.22% 38.08% -25.41% 23.05% 15.39% 56.67% -1,302.54%
Free Cash Flow Firm Growth		 -255.83% 25.92% 21.41% 53.94% -134.08% 66.89% -89.60% 64.34% -33.02% -6,592.24% 89.53%
Invested Capital Growth		 -10.63% -36.92% -2.16% -27.68% 18.73% -13.70% 18.52% -29.37% -7.73% 667.32% -41.86%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 91.18% -129.94% 2.12% -55.47% 71.11% -240.29% 3.77% 6.39% 30.83% -6.53% -4.54%
EBIT Q/Q Growth		 17.51% -14.99% 3.12% -12.91% 48.88% -470.41% -1.34% 6.26% 19.80% -6.58% -3.90%
NOPAT Q/Q Growth		 -66.47% 29.01% 13.12% -14.17% 6.48% -7.91% 6.03% 17.98% -3.39% -6.28% 1.02%
Net Income Q/Q Growth		 -12.26% 13.46% 2.91% -3.21% 37.18% -332.45% -26.17% 5.56% 17.62% -6.73% -2.73%
EPS Q/Q Growth		 -351.40% 60.28% -17,955.56% 95.24% 87.66% 0.00% -26.17% 0.55% 42.62% -6.73% -127.16%
Operating Cash Flow Q/Q Growth		 -53.42% 45.25% 6.60% 8.09% -14.44% 18.70% -13.85% 17.41% -9.61% 29.28% -36.18%
Free Cash Flow Firm Q/Q Growth		 -2,015.18% 54.26% 8.86% 48.03% -52.77% 22.10% -19.49% 41.67% -21.91% 2.11% -38.25%
Invested Capital Q/Q Growth		 62.95% 2.00% 8.59% -82.18% -0.38% -18.25% 0.66% -7.71% -2.29% -19.01% -16.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.24% 96.26% 97.52% 98.03% 97.24% 94.70% 97.97% 95.35% 93.38% 100.00% 100.00%
Interest Burden Percent		 219.08% 164.41% 154.22% 101.91% 152.59% 122.92% 127.23% 122.19% 145.67% 102.50% 101.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 334.96% 196.51% 115.46% 104.19% 119.37% 60.39% 87.28% 86.65% 52.80% -1,163.67% -161.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -372.16% -49.27%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 335.56% 196.76% 115.55% 104.29% 119.52% 60.48% 87.42% 86.72% 52.80% -1,163.67% -161.86%
Return on Equity Simple (ROE_SIMPLE)		 366.83% 144.58% 104.25% 133.88% 130.19% 66.04% 87.91% 85.35% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.83 -4.02 -2.77 -1.83 -2.45 -1.27 -1.39 -1.24 -1.08 -40 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 327.53% 171.21% 105.46% 124.02% 145.90% 71.69% 152.93% 180.37% 96.65% 1,321.95% 765.03%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 37.73% -257.45% -129.07%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.33 -4.97 -4.68 -5.76 -3.20 -1.74 -2.13 -2.28 -1.34 -57 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.13 -1.89 -2.04 -5.37 -1.62 -1.40 -1.63 -1.83 -0.74 -57 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.18
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.14
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.47 -0.64 -0.70 -0.39 -0.43 -0.20 -0.32 -0.16 -0.25 0.12 0.05
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.01 0.00
Financial Leverage		 -0.50 -0.56 -0.66 -0.57 -0.40 -0.32 -0.27 -0.26 -0.22 0.28 0.07
Leverage Ratio		 -0.18 -0.06 -0.01 -0.02 -0.03 -0.02 -0.02 -0.02 -0.02 1.95 1.39
Compound Leverage Factor		 -0.39 -0.10 -0.02 -0.02 -0.04 -0.02 -0.02 -0.03 -0.03 1.99 1.41
Debt to Total Capital		 -88.55% -177.70% -228.94% -62.69% -74.76% -25.57% -47.78% -19.34% -32.59% 10.71% 4.67%
Short-Term Debt to Total Capital		 -88.55% -177.70% -228.94% -62.69% -74.76% -25.57% -47.78% -19.34% -30.53% 10.03% 4.67%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.06% 0.68% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% -0.19% 0.00% -0.20% -0.24% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 188.92% 277.95% 329.19% 162.88% 175.00% 125.77% 148.02% 119.34% 132.59% 89.29% 95.33%
Debt to EBITDA		 -8.97 -1.84 -2.30 -0.31 -0.96 -0.45 -0.60 -0.28 -1.25 -0.03 -0.03
Net Debt to EBITDA		 -8.07 -1.81 -2.29 -0.31 -0.92 -0.44 -0.60 -0.27 -1.22 -0.03 0.02
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 0.00 0.00
Debt to NOPAT		 -0.25 -0.87 -1.70 -0.91 -0.64 -0.49 -0.70 -0.41 -0.86 -0.04 -0.04
Net Debt to NOPAT		 -0.22 -0.85 -1.69 -0.90 -0.61 -0.49 -0.70 -0.40 -0.84 -0.04 0.03
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.05 0.00 0.00
Altman Z-Score		 0.00 -804.22 -1,218.01 -940.72 -944.42 -6,939.27 -1,138.02 -1,688.42 -1,413.88 -18.45 -19.84
Noncontrolling Interest Sharing Ratio		 -0.18% -0.12% -0.08% -0.09% -0.13% -0.15% -0.16% -0.08% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.12 0.01 0.01 0.02 0.02 0.00 0.00 0.01 0.01 1.50 2.55
Quick Ratio		 0.04 0.01 0.00 0.00 0.02 0.00 0.00 0.00 0.01 0.00 0.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.69 -3.47 -2.73 -1.26 -2.94 -0.97 -1.85 -0.66 -0.88 -59 -6.14
Operating Cash Flow to CapEx		 -45,566.34% 0.00% 0.00% -71,678.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -115,196.33%
Free Cash Flow to Firm to Interest Expense		 -0.91 -1.08 -1.08 -11.39 -1.75 -2.44 -3.15 -1.30 -1.43 -40.86 -20.63
Operating Cash Flow to Interest Expense		 -0.87 -0.64 -0.86 -18.68 -1.10 -2.87 -2.45 -2.18 -1.53 -0.28 -19.10
Operating Cash Flow Less CapEx to Interest Expense		 -0.87 -0.64 -0.86 -18.70 -1.10 -2.87 -2.45 -2.18 -1.53 -0.28 -19.12
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.04 0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 8,916.17 9,678.86 15,252.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.48 -2.03 -2.07 -2.65 -2.15 -2.45 -1.99 -2.58 -2.78 16 9.16
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.14 -0.55 -0.04 -0.57 0.50 -0.29 0.45 -0.59 -0.20 19 -6.59
Enterprise Value (EV)		 0.00 6.82 5.76 3.44 1.59 0.78 252 0.73 0.91 1.69 1.31
Market Capitalization		 0.00 3.40 1.08 1.78 0.10 0.16 251 0.23 0.00 0.03 1.69
Book Value per Share		 $0.00 ($1.45) ($0.18) ($0.01) ($0.08) ($0.51) ($0.02) $0.00 ($0.02) $1.20 $0.17
Tangible Book Value per Share		 $0.00 ($1.45) ($0.18) ($0.01) ($0.08) ($0.51) ($0.02) $0.00 ($0.02) $1.20 $0.17
Total Capital		 -1.36 -1.96 -2.05 -2.64 -2.08 -2.44 -2.05 -2.61 -2.85 16 9.86
Total Debt		 1.20 3.48 4.70 1.66 1.56 0.62 0.98 0.51 0.93 1.67 0.46
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.11 0.00
Net Debt		 1.08 3.41 4.68 1.65 1.49 0.62 0.97 0.50 0.91 1.66 -0.37
Capital Expenditures (CapEx)		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.50 -2.04 -2.08 -2.66 -2.18 -2.45 -2.07 -2.64 -2.92 4.32 4.82
Debt-free Net Working Capital (DFNWC)		 -1.38 -1.97 -2.06 -2.65 -2.11 -2.45 -2.07 -2.63 -2.90 4.34 5.65
Net Working Capital (NWC)		 -2.58 -5.45 -6.76 -4.31 -3.67 -3.07 -3.05 -3.14 -3.77 2.77 5.19
Net Nonoperating Expense (NNE)		 4.58 3.85 4.27 3.93 2.29 0.76 1.26 1.42 0.75 19 6.13
Net Nonoperating Obligations (NNO)		 1.08 3.41 4.68 1.65 1.49 0.62 1.03 0.54 1.00 1.85 -0.24
Total Depreciation and Amortization (D&A)		 4.19 3.08 2.64 0.39 1.57 0.34 0.51 0.46 0.60 0.32 0.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($10,000,000,000.00) ($1,120,000,000,000.00) ($180,000,000,000.00) ($10,970,000,000.00) ($190,000,000.00) ($800,000.00) ($50,000.00) ($1.80) ($0.02) ($371.25) ($17.62)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 1.00 41.00 68.00 1.74M 85.05M 158.73K 1.12M
Adjusted Diluted Earnings per Share		 ($10,000,000,000.00) ($1,120,000,000,000.00) ($180,000,000,000.00) ($10,970,000,000.00) ($190,000,000.00) ($800,000.00) $0.00 ($1.80) ($0.02) ($371.25) ($17.62)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 1.00 41.00 677.00 1.74M 85.05M 158.73K 1.12M
Adjusted Basic & Diluted Earnings per Share		 ($10,000,000,000.00) ($1,120,000,000,000.00) ($180,000,000,000.00) ($10,970,000,000.00) ($190,000,000.00) ($800,000.00) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 3.00 677.00 14.83M 688.02M 512.27K 6.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.83 -4.02 -2.77 -1.83 -2.45 -1.27 -1.39 -1.24 -1.08 -40 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -0.84 -1.55 -1.84 -52.25 -1.90 -4.36 -3.64 -4.51 -2.19 -40.07 -62.41
NOPAT to Interest Expense		 -0.94 -1.25 -1.09 -16.59 -1.45 -3.18 -2.38 -2.45 -1.76 -27.94 -42.79
EBIT Less CapEx to Interest Expense		 -0.84 -1.55 -1.84 -52.28 -1.90 -4.36 -3.64 -4.51 -2.19 -40.07 -62.43
NOPAT Less CapEx to Interest Expense		 -0.94 -1.25 -1.09 -16.62 -1.45 -3.18 -2.38 -2.45 -1.76 -27.94 -42.81
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Propanc Biopharma

This table displays calculated financial ratios and metrics derived from Propanc Biopharma's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 22,258,941.00 52,144,948.00 167,978,843.00 688,022,017.00 789,899,183.00 15,372.00 11,611,782.00 12,806,747.00 13,364,244.00 15,859,280.00 56,959,280.00
DEI Adjusted Shares Outstanding		 22,258,941.00 52,144,948.00 167,978,843.00 688,022,017.00 789,899,183.00 615.00 464,471.00 12,806,747.00 13,364,244.00 634,371.00 2,278,371.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.03 -0.01 0.00 0.00 0.00 -87,914.38 -8.77 -0.38 -0.30 -10.03 -2.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 57.35% 44.81% 59.57% -347.63% -5.07% -19,276.69% -1,559.64% -2,235.15% -1,320.83% 88.25% -21.32%
EBIT Growth		 19.89% 39.86% 52.74% -24.06% 34.76% -13,616.57% -1,198.80% -1,741.38% -941.71% 88.23% -18.14%
NOPAT Growth		 27.95% -8.97% -24.00% 30.30% 51.29% -12,523.63% -1,302.56% -1,507.20% -1,612.77% 87.95% 5.16%
Net Income Growth		 -20.39% 34.96% 52.06% -0.98% 26.39% -10,165.30% -1,035.45% -1,265.40% -618.62% 88.24% -12.32%
EPS Growth		 -20.39% 34.96% 148,980.43% -89,825.00% 97.93% 97.71% -1,035.45% 98.92% 99.07% 97.76% 84.13%
Operating Cash Flow Growth		 -6.06% 46.66% -46.07% 29.37% 107.84% 6.43% 64.54% -723.33% -5,434.72% -1,087.62% -1,637.77%
Free Cash Flow Firm Growth		 147.86% -77.07% -96.05% 263.60% -36.96% -221,301.93% -121,885.26% -4,925.96% -16,334.50% 106.64% 119.80%
Invested Capital Growth		 -22.44% -13.43% -7.73% -27.72% -9.85% 816.57% 667.32% 598.58% 510.80% -43.30% -41.86%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -363.83% -35.97% 17.89% 13.56% -8.88% -24,974.40% 92.97% -23.58% 33.75% -107.32% 27.37%
EBIT Q/Q Growth		 -116.64% 13.67% 23.52% 13.27% -13.91% -18,053.00% 92.76% -24.88% 35.56% -105.06% 27.29%
NOPAT Q/Q Growth		 -5.00% 3.93% 38.25% -11.89% 26.62% -24,798.40% 93.14% -28.21% 21.80% -75.12% 45.99%
Net Income Q/Q Growth		 -66.55% 9.87% 31.92% 1.19% -21.41% -12,468.45% 92.47% -18.82% 36.10% -105.74% 28.10%
EPS Q/Q Growth		 -66.55% 9.87% 225.48% -105.25% 10.40% 61.22% 92.47% -101.31% 23.08% 6.67% -1,353.57%
Operating Cash Flow Q/Q Growth		 28.36% 56.96% -152.86% 9.41% 107.95% -613.62% 4.17% -7,032.59% 48.47% -14.34% -40.22%
Free Cash Flow Firm Q/Q Growth		 40.99% -83.89% -35.49% 2,381.50% -75.56% -56,629.11% 64.48% 1.67% 17.77% 123.13% 5.85%
Invested Capital Q/Q Growth		 -13.07% -5.13% -2.29% -5.04% 2.75% 785.78% -19.01% -7.69% -19.87% -5.35% -16.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 81.96% 99.95% 99.93% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 159.03% 136.14% 121.20% 137.99% 147.08% 101.83% 105.88% 102.32% 101.46% 101.80% 100.67%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 76.96% 66.56% 52.80% 51.40% 43.25% -767.20% -1,163.67% -1,236.83% -1,811.69% -126.98% -161.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -307.91% -372.16% -416.88% -515.46% -29.13% -49.27%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 77.02% 66.56% 52.80% 51.40% 43.25% -767.20% -1,163.67% -1,236.83% -1,563.29% -122.59% -161.86%
Return on Equity Simple (ROE_SIMPLE)		 69.96% 59.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.31 -0.29 -0.18 -0.20 -0.15 -37 -2.55 -3.27 -2.56 -4.48 -2.42
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 31.06% 30.27% 22.91% 15.89% 24.38% 1,440.29% 106.70% 228.36% 70.06% 241.32% 268.61%
Return On Investment Capital (ROIC_SIMPLE)		 11.90% 10.55% 6.38% 6.74% 5.05% -192.32% -16.38% -21.82% -23.16% -43.29% -24.54%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -0.45 -0.39 -0.30 -0.26 -0.29 -53 -3.85 -4.73 -3.05 -6.25 -4.54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.20 -0.27 -0.22 -0.19 -0.21 -53 -3.73 -4.54 -3.00 -6.23 -4.52
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.46 0.69 0.24 0.18
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.46 0.69 0.24 0.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.06 0.11 1.44 0.70 0.31 0.14
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.28 -0.25 -0.25 -0.27 -0.29 0.07 0.12 0.04 0.05 0.05 0.05
Long-Term Debt to Equity		 -0.01 -0.01 -0.02 -0.02 -0.02 0.01 0.01 0.00 0.00 0.00 0.00
Financial Leverage		 -0.28 -0.23 -0.22 -0.27 -0.30 0.16 0.28 0.13 0.21 0.05 0.07
Leverage Ratio		 -0.05 -0.03 -0.02 -0.03 -0.04 1.57 1.95 1.76 2.08 1.27 1.39
Compound Leverage Factor		 -0.09 -0.04 -0.02 -0.05 -0.06 1.60 2.06 1.80 2.11 1.30 1.40
Debt to Total Capital		 -38.31% -32.53% -32.59% -36.08% -40.64% 6.44% 10.71% 4.22% 4.92% 4.58% 4.67%
Short-Term Debt to Total Capital		 -36.94% -30.85% -30.53% -33.74% -37.86% 5.95% 10.03% 4.22% 4.92% 4.58% 4.67%
Long-Term Debt to Total Capital		 -1.37% -1.68% -2.06% -2.33% -2.78% 0.49% 0.68% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.30% 8.81% 0.00%
Common Equity to Total Capital		 138.31% 132.53% 132.59% 136.08% 140.64% 93.56% 89.29% 95.78% 86.78% 86.60% 95.33%
Debt to EBITDA		 -0.76 -0.85 -1.25 -1.22 -1.33 -0.02 -0.03 -0.01 -0.01 -0.03 -0.03
Net Debt to EBITDA		 -0.71 -0.84 -1.22 -1.21 -1.31 -0.02 -0.03 0.00 0.00 0.00 0.02
Long-Term Debt to EBITDA		 -0.03 -0.04 -0.08 -0.08 -0.09 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.97 -0.87 -0.86 -1.10 -1.45 -0.03 -0.04 -0.01 -0.01 -0.04 -0.04
Net Debt to NOPAT		 -0.90 -0.87 -0.84 -1.09 -1.43 -0.03 -0.04 0.00 0.00 -0.01 0.03
Long-Term Debt to NOPAT		 -0.03 -0.05 -0.05 -0.07 -0.10 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -404.48 -2,639.79 -1,366.34 -1,565.21 -1,278.51 -15.04 -9.43 -7.20 -11.62 -14.39 -16.21
Noncontrolling Interest Sharing Ratio		 -0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.71% 3.46% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.06 0.00 0.01 0.01 0.00 2.24 1.50 2.45 2.13 2.37 2.55
Quick Ratio		 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.17 0.15 0.13 0.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.17 0.03 0.02 0.43 0.10 -59 -21 -21 -17 3.94 4.17
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -77,842.91% -44,073.22% -741,848.05% -7,628,485.71%
Free Cash Flow to Firm to Interest Expense		 0.63 0.19 0.28 4.40 0.76 -64.94 -73.83 -188.81 -381.88 35.05 136.68
Operating Cash Flow to Interest Expense		 -0.90 -0.73 -4.14 -2.41 0.14 -0.11 -0.32 -17.66 -22.38 -10.15 -52.46
Operating Cash Flow Less CapEx to Interest Expense		 -0.90 -0.73 -4.14 -2.41 0.14 -0.11 -0.32 -17.68 -22.43 -10.16 -52.46
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.58 -2.71 -2.78 -2.92 -2.84 19 16 15 12 11 9.16
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.47 -0.32 -0.20 -0.63 -0.25 22 19 17 14 -8.42 -6.59
Enterprise Value (EV)		 1.20 1.09 0.91 1.08 1.19 1.23 1.69 21 8.20 3.45 1.31
Market Capitalization		 0.29 0.19 0.00 0.00 0.00 0.03 0.03 21 7.17 2.38 1.69
Book Value per Share		 ($0.16) ($0.07) ($0.02) ($0.02) ($0.01) $1,176.96 $1.20 $1.12 $0.78 $0.62 $0.17
Tangible Book Value per Share		 ($0.16) ($0.07) ($0.02) ($0.02) ($0.01) $1,176.96 $1.20 $1.12 $0.78 $0.62 $0.17
Total Capital		 -2.58 -2.79 -2.85 -3.02 -2.96 19 16 15 12 11 9.86
Total Debt		 0.99 0.91 0.93 1.09 1.20 1.25 1.67 0.63 0.59 0.52 0.46
Total Long-Term Debt		 0.04 0.05 0.06 0.07 0.08 0.09 0.11 0.00 0.00 0.00 0.00
Net Debt		 0.92 0.90 0.91 1.08 1.19 1.19 1.66 0.03 0.03 0.08 -0.37
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.67 -2.82 -2.92 -3.07 -3.03 6.50 4.32 5.22 4.11 4.82 4.82
Debt-free Net Working Capital (DFNWC)		 -2.60 -2.81 -2.90 -3.06 -3.02 6.55 4.34 5.82 4.68 5.27 5.65
Net Working Capital (NWC)		 -3.55 -3.68 -3.77 -4.08 -4.14 5.39 2.77 5.19 4.08 4.75 5.19
Net Nonoperating Expense (NNE)		 0.28 0.23 0.18 0.15 0.28 17 1.52 1.57 0.53 1.88 2.15
Net Nonoperating Obligations (NNO)		 0.98 0.99 1.00 1.19 1.32 1.36 1.85 0.18 0.20 0.20 -0.24
Total Depreciation and Amortization (D&A)		 0.25 0.11 0.07 0.06 0.08 0.06 0.12 0.19 0.04 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1,800.00) ($600.00) $684.85 $0.00 ($32.23) ($312.50) ($641.25) ($0.39) ($0.30) ($7.00) ($4.07)
Adjusted Weighted Average Basic Shares Outstanding		 397.00 994.00 1.42K 590.94M 13.35K 173.04K 6.35K 12.33M 13.36M 897.10K 1.12M
Adjusted Diluted Earnings per Share		 ($1,800.00) ($600.00) $684.85 $0.00 ($32.23) ($312.50) ($641.25) ($0.39) ($0.30) ($7.00) ($4.07)
Adjusted Weighted Average Diluted Shares Outstanding		 397.00 994.00 1.42K 590.94M 13.35K 173.04K 6.35K 12.33M 13.36M 897.10K 1.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($641.25) $0.00 $0.00 $0.00 ($4.07)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 869.00 2.80K 688.02M 789.90M 15.37K 464.47K 512.27K 13.36M 15.86M 2.28M 6.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.31 -0.29 -0.18 -0.20 -0.15 -37 -2.55 -3.27 -2.56 -4.48 -2.42
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1.69 -2.77 -4.72 -2.63 -2.12 -58.09 -13.47 -43.06 -68.26 -55.53 -148.76
NOPAT to Interest Expense		 -1.16 -2.11 -2.90 -2.09 -1.08 -40.69 -8.94 -29.80 -57.31 -39.82 -79.25
EBIT Less CapEx to Interest Expense		 -1.69 -2.77 -4.72 -2.63 -2.12 -58.09 -13.47 -43.09 -68.31 -55.54 -148.76
NOPAT Less CapEx to Interest Expense		 -1.16 -2.11 -2.90 -2.09 -1.08 -40.69 -8.94 -29.82 -57.36 -39.82 -79.25
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Propanc Biopharma (NASDAQ:PPCB) remains a pre-revenue biotechnology company with substantial operating losses and recurring cash needs. Revenue was reported at zero in each provided 2025 and 2026 income statement. Net losses were $4.1 million in Q4 2025, $4.8 million in Q1 2026, $3.1 million in Q2 2026 and $6.4 million in Q3 2026. The Q4 2026 statement reported an additional $4.6 million loss. Although the Q2 loss was lower than in the surrounding quarters, there is no evidence of a sustainable improvement in profitability.

Operating expenses have been volatile and have generally increased from the 2024 levels. Selling, general and administrative expense rose from $0.2 million in Q4 2024 to $6.2 million in Q3 2026, before falling to $0.8 million in Q4 2026. Research and development spending has remained comparatively modest, ranging from approximately $20,000 to $170,000 in the recent 2026 quarters. The large swings in SG&A and other operating expenses, including unusually large amounts in the 2025 restated quarters, make the company’s underlying cost structure difficult to assess.

Cash flow shows continued dependence on external financing. Operating cash outflow was $1.9 million in Q1 2026, $1.0 million in Q2, $1.1 million in Q3 and $1.6 million in Q4. Financing inflows, including common equity issuance, debt activity and other financing, offset much of that burn and produced a $388,000 increase in cash during Q4 2026. However, cash balances declined from $603,000 at September 30, 2025, to $444,000 at March 31, 2026, before the later-quarter financing-supported activity.

The balance sheet has improved substantially from the severe capital deficit reported at December 31, 2024, when total equity was negative $4.2 million. By March 31, 2026, total equity had risen to $9.8 million and total assets stood at $14.3 million. Nevertheless, much of the asset base consists of prepaid expenses and other noncurrent operating assets rather than cash or property. Common equity also appears to have been supported by significant equity issuance, while weighted-average shares increased dramatically over the period, creating material dilution risk for existing shareholders.

  • Financing has provided near-term liquidity support: Q4 2026 financing activities generated approximately $2.0 million, contributing to a $388,000 increase in cash despite a $1.6 million operating cash outflow.
  • Balance-sheet equity recovered from a deficit: Total equity improved from negative $4.2 million at December 31, 2024, to positive $9.8 million at March 31, 2026.
  • Debt levels have moderated compared with earlier periods: Long-term debt was zero in the Q1-Q3 2026 balance sheets, while short-term debt declined to approximately $520,000 by March 31, 2026.
  • Capital expenditures remain minimal: Property, plant and equipment purchases were only $21 in Q4 2026, suggesting the company is not currently relying on significant capital investment to fund operations.
  • Noncash adjustments materially affect reported results: Large noncash reconciliation items, including $2.9 million in Q4 2026, reduced the direct comparability between accounting losses and operating cash burn.
  • The company has not generated operating revenue: Revenue and gross profit were zero in all provided 2025 and 2026 income statements.
  • Losses remain persistent: Propanc recorded losses in every reported quarter, including a $6.4 million loss in Q3 2026 and a $4.6 million loss in Q4 2026.
  • Operating cash flow remains negative: Every provided 2026 cash flow statement showed cash used in operations, with cumulative 2026 operating outflows of roughly $5.8 million across Q1-Q4.
  • External financing is essential: The company’s cash inflows have primarily come from debt, equity issuance and other financing rather than from business operations, increasing refinancing and funding risk.
  • Shareholder dilution is substantial: Weighted-average basic shares increased from 1,417 in Q4 2024 to 1.1 million in Q4 2026, while the balance sheet shows a sharp increase in common stock, indicating that future capital raising could continue to dilute existing investors.
11/13/26 01:45 AM ETAI Generated. May Contain Errors.

Propanc Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Propanc Biopharma's financial year ends in June. Their financial year 2026 ended on June 30, 2026.

Propanc Biopharma's net income appears to be on a downward trend, with a most recent value of -$18.86 million in 2026, falling from -$9.41 million in 2016. The previous period was -$58.92 million in 2025. Find out what analysts predict for Propanc Biopharma in the coming months.

Propanc Biopharma's total operating income in 2026 was -$18.19 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $18.19 million

Over the last 10 years, Propanc Biopharma's total revenue changed from $0.00 in 2016 to $0.00 in 2026, a change of 0.0%.

In the past 9 quarters, Propanc Biopharma's cash and equivalents has ranged from $6.22 thousand in Q3 2024 to $602.74 thousand in Q1 2026, and is currently $443.70 thousand as of their latest financial filing in Q3 2026.

Propanc Biopharma had total debt of $460.81 thousand at the end of 2026, a 72.4% decrease from 2025, and a 61.8% decrease since 2016.

Over the last 10 years, Propanc Biopharma's book value per share changed from 0.00 in 2016 to 0.17 in 2026.


Related Companies

Financial statements for NASDAQ:PPCB last updated on 10/26/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel